Patents by Inventor Daniel Deaver

Daniel Deaver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Morphinan Derivatives with High Oral Bioavailability
    Publication number: 20200383970
    Abstract: The instant application relates to morphinan derivatives of formula I with enhanced oral bioavailability for the treatment of diseases associated with opioid receptor activity or blockade including alcohol and opiate addiction.
    Type: Application
    Filed: January 10, 2020
    Publication date: December 10, 2020
    Inventors: Ryan Turncliff, Daniel Deaver, Derrick Arnelle
  • Opioid agonist antagonist combinations
    Patent number: 10758527
    Abstract: The invention relates a composition comprising an opioid agonist and Compound-1:
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: September 1, 2020
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Methods for treating antipsychotic-induced weight gain
    Patent number: 10716785
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: July 21, 2020
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Mark Todtenkopf
  • METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN
    Publication number: 20190307742
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Application
    Filed: April 22, 2019
    Publication date: October 10, 2019
    Inventors: Daniel Deaver, Mark Todtenkopf
  • OPIOID AGONIST ANTAGONIST COMBINATIONS
    Publication number: 20190192505
    Abstract: The invention relates a composition comprising an opioid agonist and Compound-1:
    Type: Application
    Filed: December 13, 2018
    Publication date: June 27, 2019
    Inventors: Daniel Deaver, Elliot Ehrich
  • Compositions of buprenorphine and ? antagonists
    Patent number: 10314838
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ c ma ? ? x ? ( BUP ) / EC 50 ] [ c ma ? ? x ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: June 11, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Methods for treating antipsychotic-induced weight gain
    Patent number: 10300054
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: May 28, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Mark Todtenkopf
  • Opioid agonist antagonist combinations
    Patent number: 10195191
    Abstract: The invention relates a composition comprising an opioid agonist and Compound-1:
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: February 5, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Compositions of buprenorphine and ? antagonists
    Patent number: 10188643
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: January 29, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN
    Publication number: 20180271855
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Application
    Filed: March 16, 2018
    Publication date: September 27, 2018
    Inventors: Daniel Deaver, Mark Todtenkopf
  • Methods for treating antipsychotic-induced weight gain
    Patent number: 9943514
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: April 17, 2018
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Mark Todtenkopf
  • COMPOSITIONS OF BUPRENORPHINE AND ? ANTAGONISTS
    Publication number: 20180078542
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ c ma ? ? x ? ( BUP ) / EC 50 ] [ c ma ? ? x ? ( ANTAGONIST ) / IC 50 ] .
    Type: Application
    Filed: September 28, 2017
    Publication date: March 22, 2018
    Inventors: Daniel Deaver, Elliot Ehrich
  • Compositions of Buprenorphine and ? Antagonists
    Publication number: 20180078543
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Application
    Filed: October 2, 2017
    Publication date: March 22, 2018
    Inventors: Daniel Deaver, Elliot Ehrich
  • Compositions of buprenorphine and ? antagonists
    Patent number: 9918978
    Abstract: The invention relates to a composition comprising buprenorphine and ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: March 20, 2018
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Compositions of buprenorphine and ? antagonists
    Patent number: 9913837
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: March 13, 2018
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Opioid Agonist Antagonist Combinations
    Publication number: 20170136004
    Abstract: The invention relates a composition comprising an opioid agonist and Compound-1:
    Type: Application
    Filed: November 16, 2015
    Publication date: May 18, 2017
    Inventors: Daniel Deaver, Elliot Ehrich
  • Methods for Treating Antipsychotic-Induced Weight Gain
    Publication number: 20170119757
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Application
    Filed: November 3, 2016
    Publication date: May 4, 2017
    Inventors: Daniel Deaver, Mark Todtenkopf
  • Morphinan Derivatives with High Oral Bioavailability
    Publication number: 20170112827
    Abstract: The instant application relates to morphinan derivatives of formula I with enhanced oral bioavailability for the treatment of diseases associated with opioid receptor activity or blockade including alcohol and opiate addiction.
    Type: Application
    Filed: November 17, 2016
    Publication date: April 27, 2017
    Inventors: Ryan Turncliff, Daniel Deaver, Derrick Arnelle
  • COMPOSITIONS OF BUPRENORPHINE AND u ANTAGONISTS
    Publication number: 20170056392
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Application
    Filed: September 12, 2016
    Publication date: March 2, 2017
    Inventors: Daniel Deaver, Elliot Ehrich
  • Selective Opioid Compounds
    Publication number: 20170042882
    Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which relates to mophinan compounds useful as ?, ? and/or ? receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.
    Type: Application
    Filed: August 17, 2016
    Publication date: February 16, 2017
    Inventors: Derrick Arnelle, Daniel Deaver, Reginald L. Dean, III, Mark Todtenkopf